Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.

Angiotensin-Converting Enzyme 2 / metabolism Animals Antibodies, Monoclonal / immunology Antibodies, Monoclonal, Humanized / immunology Antibodies, Neutralizing / immunology Antibodies, Viral / blood Antigenic Drift and Shift / genetics Broadly Neutralizing Antibodies / immunology COVID-19 Vaccines / immunology Cell Line Convalescence Epitopes, B-Lymphocyte / immunology Humans Immune Evasion Mice Neutralization Tests SARS-CoV-2 / chemistry Spike Glycoprotein, Coronavirus / chemistry Vesiculovirus / genetics

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
02 2022
Historique:
received: 12 12 2021
accepted: 23 12 2021
pubmed: 12 1 2022
medline: 3 3 2022
entrez: 11 1 2022
Statut: ppublish

Résumé

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising concerns about the effectiveness of available vaccines and antibody-based therapeutics. Here we show that the Omicron RBD binds to human ACE2 with enhanced affinity, relative to the Wuhan-Hu-1 RBD, and binds to mouse ACE2. Marked reductions in neutralizing activity were observed against Omicron compared to the ancestral pseudovirus in plasma from convalescent individuals and from individuals who had been vaccinated against SARS-CoV-2, but this loss was less pronounced after a third dose of vaccine. Most monoclonal antibodies that are directed against the receptor-binding motif lost in vitro neutralizing activity against Omicron, with only 3 out of 29 monoclonal antibodies retaining unaltered potency, including the ACE2-mimicking S2K146 antibody

Identifiants

DOI: 10.1038/s41586-021-04386-2 PMID: 35016195 PMC: PMC9531318
pubmed: 35016195
doi: 10.1038/s41586-021-04386-2
pii: 10.1038/s41586-021-04386-2
pmc: PMC9531318
mid: NIHMS1830838
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Monoclonal, Humanized 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Broadly Neutralizing Antibodies 0
COVID-19 Vaccines 0
Epitopes, B-Lymphocyte 0
S2H97 antibody 0
S2X259 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
sotrovimab 1MTK0BPN8V
ACE2 protein, human EC 3.4.17.23
Ace2 protein, mouse EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

664-670

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM120553
Pays : United States
Organisme : NIAID NIH HHS
ID : DP1 AI158186
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201700059C
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93021C00014
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI151698
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008268
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Park, Y. J. et al. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science https://doi.org/10.1126/science.abm8143 (2022).
Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
pubmed: 32422645 doi: 10.1038/s41586-020-2349-y
Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 597, 103–108 (2021).
pubmed: 34280951 doi: 10.1038/s41586-021-03817-4
Starr, T. N. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature 597, 97–102 (2021).
pubmed: 34261126 doi: 10.1038/s41586-021-03807-6
Telenti, A. et al. After the pandemic: perspectives on the future trajectory of COVID-19. Nature 596, 495–504 (2021).
pubmed: 34237771 doi: 10.1038/s41586-021-03792-w
Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130–135 (2021).
pubmed: 33684923 doi: 10.1038/s41586-021-03398-2
Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 27, 717–726 (2021).
pubmed: 33664494 pmcid: 8058618 doi: 10.1038/s41591-021-01294-w
Corti, D., Purcell, L. A., Snell, G. & Veesler, D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184, 3086–3108 (2021).
pubmed: 34087172 pmcid: 8152891 doi: 10.1016/j.cell.2021.05.005
McCallum, M. et al. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science 374, 1621–1626 (2021).
pubmed: 34751595 doi: 10.1126/science.abl8506
Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114–119 (2021).
pubmed: 34488225 pmcid: 8566220 doi: 10.1038/s41586-021-03944-y
Sheikh, A. et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397, 2461–2462 (2021).
pubmed: 34139198 pmcid: 8201647 doi: 10.1016/S0140-6736(21)01358-1
Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024–1042 (2020).
pubmed: 32991844 pmcid: 7494283 doi: 10.1016/j.cell.2020.09.037
Greaney, A. J. et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe 29, 463–476 (2021).
pubmed: 33592168 pmcid: 7869748 doi: 10.1016/j.chom.2021.02.003
Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292 (2020).
pubmed: 32155444 pmcid: 7102599 doi: 10.1016/j.cell.2020.02.058
Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature https:///doi.org/10.1038/s41586-021-04387-1 (2021).
Wilhelm, A. et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. Preprint at https://doi.org/10.1101/2021.12.07.21267432 (2021).
Andrews, N. et al. Effectiveness of COVID-19 vaccines against the Omicron variant of concern. Preprint at https://doi.org/10.1101/2021.12.14.21267615 (2021).
Cao, Y. et al. B.1.1.529 escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature https://doi.org/10.1038/s41586-021-04385-3 (2021).
Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070–1085 (2020).
pubmed: 33031744 pmcid: 7510428 doi: 10.1016/j.cell.2020.09.050
Dinnon, K. H. III et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560–566 (2020).
pubmed: 32854108 pmcid: 8034761 doi: 10.1038/s41586-020-2708-8
Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature 593, 136–141 (2021).
pubmed: 33706364 doi: 10.1038/s41586-021-03412-7
Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295–1310 (2020).
pubmed: 32841599 pmcid: 7418704 doi: 10.1016/j.cell.2020.08.012
Shuai, H. et al. Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine 73, 103643 (2021).
pubmed: 34689086 pmcid: 8530107 doi: 10.1016/j.ebiom.2021.103643
Pan, T. et al. Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Sig. Transduct. Target Ther. 6, 420 (2021).
doi: 10.1038/s41392-021-00848-1
Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization—implications for control of the COVID-19 pandemic. Cell https://doi.org/10.1016/j.cell.2021.12.032 (2021).
Nicholls, J. & Chan Chi-wai, M. HKUMed finds Omicron SARS-CoV-2 can infect faster and better than Delta in human bronchus but with less severe infection in lung. www.med.hku.hk/en/news/press/20211215-omicron-sars-cov-2-infection (2021).
Bassi, J. et al. Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. Preprint at https://doi.org/10.1101/2021.10.05.21264054 (2021).
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
pubmed: 34002089 doi: 10.1038/s41591-021-01377-8
Stamatatos, L. et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science https://doi.org/10.1126/science.abg9175 (2021).
Bergstrom, J. J., Xu, H. & Heyman, B. Epitope-specific suppression of IgG responses by passively administered specific IgG: evidence of epitope masking. Front. Immunol. 8, 238 (2017).
pubmed: 28321225 pmcid: 5337509 doi: 10.3389/fimmu.2017.00238
Baum, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014–1018 (2020).
pubmed: 32540904 doi: 10.1126/science.abd0831
Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014 (2020).
pubmed: 32540901 pmcid: 7299284 doi: 10.1126/science.abd0827
Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020).
pubmed: 32454512 doi: 10.1038/s41586-020-2381-y
Gottlieb, R. L. et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 325, 632–644 (2021).
pubmed: 33475701 pmcid: 7821080 doi: 10.1001/jama.2021.0202
Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Transl. Med. 13, eabf1906 (2021).
pubmed: 33820835 pmcid: 8284311 doi: 10.1126/scitranslmed.abf1906
Dong, J. et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat. Microbiol. 6, 1233–1244 (2021).
pubmed: 34548634 pmcid: 8543371 doi: 10.1038/s41564-021-00972-2
Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443–449 (2020).
pubmed: 32668443 pmcid: 7584396 doi: 10.1038/s41586-020-2548-6
Thomson, E. C. et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell 184, 1171–1187 (2021).
pubmed: 33621484 pmcid: 7843029 doi: 10.1016/j.cell.2021.01.037
Starr, T. N. et al. ACE2 binding is an ancestral and evolvable trait of sarbecoviruses. Preprint at https://doi.org/10.1101/2021.07.17.452804 (2021).
Lempp, F. A. et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature 598, 342–347 (2021).
pubmed: 34464958 doi: 10.1038/s41586-021-03925-1
VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med. https://doi.org/10.1038/s41591-021-01678-y (2022).
Aggarwal, A. et al. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. Preprint at https://doi.org/10.1101/2021.12.14.21267772 (2021).
FDA. Fact sheet for healthcare providers: emergency use authorization (EUA) of sotrovimab. https://www.fda.gov/media/149534/download (2021).
Tortorici, M. A. et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 370, 950–957 (2020).
pubmed: 32972994 pmcid: 7857395 doi: 10.1126/science.abe3354
McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell 184, 2332–2347 (2021).
pubmed: 33761326 pmcid: 7962585 doi: 10.1016/j.cell.2021.03.028
McCallum, M. et al. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. Science 373, 648–654 (2021).
pubmed: 34210893 doi: 10.1126/science.abi7994
Fischer, W. et al. HIV-1 and SARS-CoV-2: patterns in the evolution of two pandemic pathogens. Cell Host Microbe 29, 1093–1110 (2021).
pubmed: 34242582 pmcid: 8173590 doi: 10.1016/j.chom.2021.05.012
Kupferschmidt, K. Where did ‘weird’ Omicron come from? Science 374, 1179 (2021).
pubmed: 34855502 doi: 10.1126/science.acx9738
Corey, L. et al. SARS-CoV-2 variants in patients with immunosuppression. N. Engl. J. Med. 385, 562–566 (2021).
pubmed: 34347959 doi: 10.1056/NEJMsb2104756
Oude Munnink, B. B. et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science 371, 172–177 (2021).
pubmed: 33172935 doi: 10.1126/science.abe5901
Zang, R. et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci. Immunol. 5, eabc3582 (2020).
pubmed: 32404436 pmcid: 7285829 doi: 10.1126/sciimmunol.abc3582
Maziarz, R. T. et al. Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients. Biol. Blood Marrow Transplant. 16, 192–198 (2010).
pubmed: 19781656 doi: 10.1016/j.bbmt.2009.09.014
Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30, 772–780 (2013).
pubmed: 23329690 pmcid: 3603318 doi: 10.1093/molbev/mst010
Yamin, R. et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 599, 465–470 (2021).
pubmed: 34547765 doi: 10.1038/s41586-021-04017-w
Giroglou, T. et al. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J. Virol. 78, 9007–9015 (2004).
pubmed: 15308697 pmcid: 506966 doi: 10.1128/JVI.78.17.9007-9015.2004
Walls, A. C. et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell 184, 5432–5447 (2021).
pubmed: 34619077 pmcid: 8440233 doi: 10.1016/j.cell.2021.09.015
Kaname, Y. et al. Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64. J. Virol. 84, 3210–3219 (2010).
pubmed: 20071581 pmcid: 2838113 doi: 10.1128/JVI.02519-09
Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116–121 (2021).
pubmed: 33106671 doi: 10.1038/s41586-020-2895-3
Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587–16595 (2020).
pubmed: 32571934 pmcid: 7368255 doi: 10.1073/pnas.2009799117
Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477–488 (2021).
pubmed: 33535027 pmcid: 7839837 doi: 10.1016/j.chom.2021.01.014
VanBlargan, L. A. et al. A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. Immunity 54, 2399–2416 (2021).
pubmed: 34481543 pmcid: 8373659 doi: 10.1016/j.immuni.2021.08.016
Cathcart, A. L. et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. Preprint at https://doi.org/10.1101/2021.03.09.434607 (2021).
Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941–1950 (2021).
pubmed: 34706189 doi: 10.1056/NEJMoa2107934
Kim, C. et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat. Commun. 12, 288 (2021).
pubmed: 33436577 pmcid: 7803729 doi: 10.1038/s41467-020-20602-5
Ryu, D. K. et al. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochem. Biophys. Res. Commun. 566, 135–140 (2021).
pubmed: 34119826 pmcid: 8180667 doi: 10.1016/j.bbrc.2021.06.016
Baum, A. et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science 370, 1110–1115 (2020).
pubmed: 33037066 pmcid: 7857396 doi: 10.1126/science.abe2402
Copin, R. et al. The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell 184, 3949–3961 (2021).
pubmed: 34161776 pmcid: 8179113 doi: 10.1016/j.cell.2021.06.002
Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384, 238–251 (2021).
pubmed: 33332778 doi: 10.1056/NEJMoa2035002
Chen, P. et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N. Engl. J. Med. 384, 229–237 (2021).
pubmed: 33113295 doi: 10.1056/NEJMoa2029849
Group, A.-T. L.-C. S. et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N. Engl. J. Med. 384, 905–914 (2021).
doi: 10.1056/NEJMoa2033130
Belk, J., Deveau, L. M., Rappazzo, C. G., Walker, L. & Wec, A. PCT application WO/2021/207597: Compounds specific to coronavirus S protein and uses thereof. (Adagio Therapeutics, 2021).

Auteurs

Elisabetta Cameroni (E)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

John E Bowen (JE)

Department of Biochemistry, University of Washington, Seattle, WA, USA.
ORCID: 0000-0003-3590-9727

Laura E Rosen (LE)

Vir Biotechnology, San Francisco, CA, USA.
ORCID: 0000-0002-8030-0219

Christian Saliba (C)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Samantha K Zepeda (SK)

Department of Biochemistry, University of Washington, Seattle, WA, USA.
ORCID: 0000-0003-0005-9793

Katja Culap (K)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
ORCID: 0000-0002-0956-0018

Dora Pinto (D)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Laura A VanBlargan (LA)

Department of Medicine, Washington University of School of Medicine, St Louis, MO, USA.
ORCID: 0000-0002-8922-8946

Anna De Marco (A)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Julia di Iulio (J)

Vir Biotechnology, San Francisco, CA, USA.

Fabrizia Zatta (F)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Hannah Kaiser (H)

Vir Biotechnology, San Francisco, CA, USA.
ORCID: 0000-0002-3991-7401

Julia Noack (J)

Vir Biotechnology, San Francisco, CA, USA.

Nisar Farhat (N)

Vir Biotechnology, San Francisco, CA, USA.

Nadine Czudnochowski (N)

Vir Biotechnology, San Francisco, CA, USA.

Colin Havenar-Daughton (C)

Vir Biotechnology, San Francisco, CA, USA.
ORCID: 0000-0002-2880-3927

Kaitlin R Sprouse (KR)

Department of Biochemistry, University of Washington, Seattle, WA, USA.
ORCID: 0000-0003-0007-2226

Josh R Dillen (JR)

Vir Biotechnology, San Francisco, CA, USA.

Abigail E Powell (AE)

Vir Biotechnology, San Francisco, CA, USA.

Alex Chen (A)

Vir Biotechnology, San Francisco, CA, USA.
ORCID: 0000-0003-2620-5066

Cyrus Maher (C)

Vir Biotechnology, San Francisco, CA, USA.
ORCID: 0000-0002-6666-3574

Li Yin (L)

Vir Biotechnology, San Francisco, CA, USA.
ORCID: 0000-0003-2634-9158

David Sun (D)

Vir Biotechnology, San Francisco, CA, USA.

Leah Soriaga (L)

Vir Biotechnology, San Francisco, CA, USA.
ORCID: 0000-0001-5852-741X

Jessica Bassi (J)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Chiara Silacci-Fregni (C)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.

Claes Gustafsson (C)

ATUM, Newark, CA, USA.

Nicholas M Franko (NM)

Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
ORCID: 0000-0001-8165-6332

Jenni Logue (J)

Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
ORCID: 0000-0002-7889-8960

Najeeha Talat Iqbal (NT)

Department of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan.

Ignacio Mazzitelli (I)

Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.

Jorge Geffner (J)

Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.

Renata Grifantini (R)

National Institute of Molecular Genetics, Milan, Italy.

Helen Chu (H)

Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.

Andrea Gori (A)

Infectious Disease Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.

Agostino Riva (A)

Department of Biomedical and Clinical Sciences 'L.Sacco' (DIBIC), Università di Milano, Milan, Italy.
ORCID: 0000-0003-3171-3049

Olivier Giannini (O)

Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.

Alessandro Ceschi (A)

Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.
ORCID: 0000-0002-4308-0405

Paolo Ferrari (P)

Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
ORCID: 0000-0002-9619-3104

Pietro E Cippà (PE)

Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.
Faculty of Medicine, University of Zurich, Zurich, Switzerland.

Alessandra Franzetti-Pellanda (A)

Clinical Research Unit, Clinica Luganese Moncucco, Lugano, Switzerland.

Christian Garzoni (C)

Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.

Peter J Halfmann (PJ)

Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
ORCID: 0000-0002-1648-1625

Yoshihiro Kawaoka (Y)

Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
ORCID: 0000-0001-5061-8296

Christy Hebner (C)

Vir Biotechnology, San Francisco, CA, USA.

Lisa A Purcell (LA)

Vir Biotechnology, San Francisco, CA, USA.

Luca Piccoli (L)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
ORCID: 0000-0002-1085-6502

Matteo Samuele Pizzuto (MS)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
ORCID: 0000-0001-5776-654X

Alexandra C Walls (AC)

Department of Biochemistry, University of Washington, Seattle, WA, USA.
Howard Hughes Medical Institute, Seattle, WA, USA.
ORCID: 0000-0002-9636-8330

Michael S Diamond (MS)

Department of Medicine, Washington University of School of Medicine, St Louis, MO, USA.
Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO, USA.
ORCID: 0000-0002-8791-3165

Amalio Telenti (A)

Vir Biotechnology, San Francisco, CA, USA.
ORCID: 0000-0001-6290-7677

Herbert W Virgin (HW)

Vir Biotechnology, San Francisco, CA, USA.
Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
ORCID: 0000-0001-8580-7628

Antonio Lanzavecchia (A)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
National Institute of Molecular Genetics, Milan, Italy.

Gyorgy Snell (G)

Vir Biotechnology, San Francisco, CA, USA. gsnell@vir.bio.
ORCID: 0000-0003-1475-659X

David Veesler (D)

Department of Biochemistry, University of Washington, Seattle, WA, USA. dveesler@uw.edu.
Howard Hughes Medical Institute, Seattle, WA, USA. dveesler@uw.edu.
ORCID: 0000-0002-6019-8675

Davide Corti (D)

Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. dcorti@vir.bio.
ORCID: 0000-0002-5797-1364

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Peptide hydrolases › Exopeptidases › Carboxypeptidases › Angiotensin-converting enzyme 2 › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Eucaryotes › Animaux › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Phénomènes biologiques › Évolution biologique › Dérive génétique › Dérive et cassure antigéniques › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Anticorps neutralisants à large spectre › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Convalescence › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Épitopes › Déterminants antigéniques des lymphocytes B › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Phénomènes biologiques › Interactions hôte-microbes › Interactions hôte-pathogène › Échappement immunitaire › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Tests sérologiques › Tests de neutralisation › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales structurales › Protéines de l'enveloppe virale › Protéines de fusion virale › Glycoprotéine de spicule des coronavirus › Broadly neutralizing antibodies overcome...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Mononegavirales › Rhabdoviridae › Vesiculovirus › Broadly neutralizing antibodies overcome...